Pfizer Inc. / Akcea Therapeutics / Ionis Pharmaceuticals (AKCEA-ANGPTL3-LRx license)
2019 · Licensing/Option · $1.3B · Terminated
Announcement Sentiment
56
Neutral / mixed
Ionis/Akcea licensed exclusive worldwide rights to AKCEA-ANGPTL3-LRx (later vupanorsen) to Pfizer for $250M upfront and up to $1.3 billion in development, regulatory and sales milestones, plus tiered royalties starting in the low- to high-teens. Pfizer terminated the collaboration in early 2022.